---
title: "NVO.US (NVO.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/NVO.US/news.md"
symbol: "NVO.US"
name: "NVO.US"
parent: "https://longbridge.com/en/quote/NVO.US.md"
datetime: "2026-05-20T01:33:33.398Z"
locales:
  - [en](https://longbridge.com/en/quote/NVO.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NVO.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NVO.US/news.md)
---

# NVO.US (NVO.US) — Related News

### [Wegovy Liver Data Broadens Semaglutide Story For Novo Nordisk Investors](https://longbridge.com/en/news/286980981.md)
*2026-05-20T00:27:57.000Z*
> Novo Nordisk presented new data on semaglutide (Wegovy) at the EASL 2026 congress, highlighting its liver safety and eff

### [](https://longbridge.com/en/news/286912169.md)
*2026-05-19T12:27:38.000Z*
> Novo Nordisk's upcoming data will show that its semaglutide can address the liver disease crisis affecting approximately

### [CDSCO asks states, UTs to monitor surrogate promotion for GLP-1 drugs](https://longbridge.com/en/news/286925029.md)
*2026-05-19T05:48:58.000Z*
> The CDSCO has instructed states and UTs to monitor promotional activities for GLP-1 weight-loss drugs like semaglutide, 

### [Report: Novo Nordisk Reports Highlights Under Price Pressure](https://longbridge.com/en/news/286780954.md)
*2026-05-18T13:37:20.000Z*
> Soren Lontoft Hansen of Sydbank pointed out that Novo Nordisk's report highlights the development of its obesity busines

### [Novo Nordisk's next weight loss battle: winning markets outside the United States](https://longbridge.com/en/news/286740414.md)
*2026-05-18T08:45:33.000Z*
> Novo Nordisk plans to launch Wegovy tablets in markets outside the United States, believing there are significant opport

### [Novo Nordisk plans to promote the launch of the oral weight loss drug Wegovy in markets outside the United States](https://longbridge.com/en/news/286732863.md)
*2026-05-18T07:45:27.000Z*
> Novo Nordisk plans to fully promote the launch of the oral weight loss drug Wegovy in markets outside the United States,

### [On the eve of a major reshuffle: After reviewing the latest financial reports of the top ten pharmaceutical companies, I see power is shifting](https://longbridge.com/en/news/286686971.md)
*2026-05-17T23:35:56.000Z*
> The global pharmaceutical industry financial report for the first quarter of 2026 shows that Eli Lilly ranks first with 

### [Nature Medicine: Targeted inhibition of miRNA to slow harmful cardiac remodeling after myocardial infarction](https://longbridge.com/en/news/286638606.md)
*2026-05-16T07:50:45.000Z*
> In a randomized phase 2 clinical trial, the miR-132 inhibitor CDR132L showed good tolerance after acute myocardial infar